Houston Methodist receives record $110M gift, names future tower

historic gift

Houston Methodist will name its forthcoming 26-story hospital facility the Brockman Centennial Tower. Rendering courtesy Houston Methodist

Houston Methodist has received the largest gift in the health system's history to establish new funds for neurological, neuroscience, and women’s health research and treatment.

The $110 million gift comes from Houston-based The Brockman Medical Research Foundation, which supports education and research in the science, medicine and healthcare fields. In response, Houston Methodist announced that it will name its forthcoming 26-story hospital facility the Brockman Centennial Tower.

The tower’s entrance will be named the Anna Margaret Bellows Centennial Hall to honor Anna Margaret Bellows, a young camper who died during the Camp Mystic flooding last summer.

“This extraordinary gift accelerates discovery and transforms how care is delivered,” Dr. Marc Boom, president and CEO of Houston Methodist, said in a news release. “We are grateful to The Brockman Medical Research Foundation for its incredible generosity and vision that will help change the lives of generations of patients. Naming Centennial Tower in recognition of this gift reflects the scale of this commitment and its impact on the future of neuroscience, neurological care and women’s health.”

The gift will be divided into two parts:

  • $100 million will go toward creating an innovation fund within the Houston Methodist Academic Institute and the Houston Methodist Neurological Institute
  • $10 million will be devoted to Houston Methodist's Department of Obstetrics and Gynecology

“This tremendous gift will accelerate translational research that broadens our understanding of neurological and other diseases,” Dr. Jenny Chang, president and CEO of the Houston Methodist Academic Institute, added in the release. “It will allow us to leverage state-of-the-art platforms to detect, diagnose and deliver therapeutics, keeping patient care at the center of our mission.”

The Brockman Centennial Tower is expected to open next year in the Texas Medical Center. Spanning more than 1 million square feet, it will house 400 patient beds, an expanded emergency department, new operating rooms and a rooftop garden. It will be connected to Houston Methodist's flagship Paula and Joseph C. “Rusty” Walter III Tower, which opened in 2018. The Centennial Tower was estimated to cost $1.4 billion when announced in 2022.

In addition to the news of the Brockman gift, Houston Methodist also announced this month that it has launched the Houston Methodist Center for Cell and Gene Therapy and tapped an internationally recognized scientist as its leader.

The new center is focused on discovering and developing innovative and cost-effective therapies for a variety of congenital and acquired diseases, including cancer, HIV and cardiovascular disease.

Dr. Malcolm Brenner has been named as the center's inaugural leader and will assume the role starting in October. He will work alongside scientists and support staff from Baylor College of Medicine and Texas Children's Hospital.

Brenner is a professor of pediatrics, medicine, molecular and human genetics and translational biology at Baylor College of Medicine. He is known for making early advances in using bone marrow transplantation as a form of cell therapy and in engineered immune-cell treatments for cancer and infections, according to a release from Houston Methodist.

“Malcolm Brenner is a pioneer in the field of cell and gene therapy and is uniquely qualified to lead Houston Methodist’s research efforts in this field,” Chang added. “His vision and leadership will play a pivotal role in advancing our work in this space.”

From Your Site Articles
March Biosciences is testing its MB-105 cell therapy in a Phase 2 clinical trial for people with difficult-to-treat cancer. Photo via march.bio

Houston cell therapy company launches second-phase clinical trial

fighting cancer

A Houston cell therapy company has dosed its first patient in a Phase 2 clinical trial. March Biosciences is testing the efficacy of MB-105, a CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma.

Last year, InnovationMap reported that March Biosciences had closed its series A with a $28.4 million raise. Now, the company, co-founded by Sarah Hein, Max Mamonkin and Malcolm Brenner, is ready to enroll a total of 46 patients in its study of people with difficult-to-treat cancer.

The trial will be conducted at cancer centers around the United States, but the first dose took place locally, at The University of Texas MD Anderson Cancer Center. Dr. Swaminathan P. Iyer, a professor in the department of lymphoma/myeloma at MD Anderson, is leading the trial.

“This represents a significant milestone in advancing MB-105 as a potential treatment option for patients with T-cell lymphoma who currently face extremely limited therapeutic choices,” Hein, who serves as CEO, says. “CAR-T therapies have revolutionized the treatment of B-cell lymphomas and leukemias but have not successfully addressed the rarer T-cell lymphomas and leukemias. We are optimistic that this larger trial will further validate MB-105's potential to address the critical unmet needs of these patients and look forward to reporting our first clinical readouts.”

The Phase 1 trial showed promise for MB-105 in terms of both safety and efficacy. That means that potentially concerning side effects, including neurological events and cytokine release above grade 3, were not observed. Those results were published last year, noting lasting remissions.

In January 2025, MB-105 won an orphan drug designation from the FDA. That results in seven years of market exclusivity if the drug is approved, as well as development incentives along the way.

The trial is enrolling its single-arm, two-stage study on ClinicalTrials.gov. For patients with stubborn blood cancers, the drug is providing new hope.

Early-stage cell therapy startup March Biosciences has partnered with CTMC. Photo via march.bio

Cancer-fighting startup partners with Houston cell therapy accelerator

marching on

When it came time to name their cell therapy startup, Houston life science innovators simply had to look to their calendar.

“I would argue that March is the best month in Houston,” Sarah Hein tells InnovationMap. “We started talking about putting this company together during COVID, so we were outside a lot. And we actually got together in March.”

That’s why the CEO and her co-founders Max Mamonkin and Malcolm Brenner decided to name their company March Biosciences.

It's a fresh, unstuffy name for a startup that has an innovative take on cancer immunotherapy. Their lead asset is an advanced cellular therapy known as MB-105, an autologous CD5 CAR T cell therapy. For patients with T-cell lymphoma and leukemia who have failed all currently available lines of therapy, the prognosis is understandably extremely poor. But in a phase one study, MB-105 has been proven to safely treat those patients. The phase two study is expected to begin in the first half of 2024.

Hein met Mamonkin at the TMC Accelerator for Cancer Therapeutics (ACT), at which the alumna of Resonant Therapeutics and Courier Therapeutics was an entrepreneur in residence.

“It's a perfect example of the opportunities here in Houston where you can go from bench to bedside, essentially, in the same institution. And Baylor has been particularly good at that because of the Center for Cell and Gene Therapy,” says Hein.

The serial entrepreneur first came to Houston as a PhD student in molecular and cellular biology at Baylor College of Medicine, but during her studies she became excited by the startup ecosystem in her new hometown. After earning her degree, she became a venture fellow at the Mercury Fund. Her experience in both science and business made her an ideal candidate to take March Biosciences to the next level.

In September, the company announced that it formed a strategic alliance with CTMC (Cell Therapy Manufacturing Center), a joint venture between MD Anderson Cancer Center and National Resilience.

“Our unique risk-sharing model allows us to collaborate with organizations like March Biosciences to accelerate the development and manufacture of innovative cell therapies, like MB-105, and bring them into the clinic with a consistent and scalable manufacturing process,” said CTMC’s CEO, Jason Bock in a press release.

The partnership “has allowed us to move really quickly,” Hein says.

That’s because what CTMC does uniquely well is take early stage companies like March Biosciences and advance them to a state that’s ready for manufacturing in a short time, around 18 months, says Hein.

According to Hein, March Biosciences’ success is a testament to Houston and its world-class medical center.

“It’s a great example of the opportunities you see here in Houston, where we have a technology that was developed by brilliant scientists here in Houston and we can pull together the resources that we need to take it to the next level,” Hein says. "Working with partners here in Houston, we have all the pieces and the community rises to the occasion to support you.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

2 leading Texas universities rank among world’s best for entrepreneurs

honor roll

The Lone Star State’s two biggest universities—the University of Texas at Austin and Texas A&M University—rank among the world’s best schools for entrepreneurs.

PitchBook’s annual list of the world’s top 100 universities for entrepreneurs takes into account both undergraduate and graduate programs. PitchBook analyzed more than 222,000 startup founders whose startups are VC-backed.

UT’s “unique” advantage

UT Austin landed at No. 10 on the list, down from No. 8 last year. PitchBook identified 1,002 UT-alumni founders at 948 startups. Collectively, those startups have raised $34.7 billion, according to PitchBook.

Among the 948 UT Austin-affiliated startups, these five have raised the most capital:

  • No. 1 Tucson, Arizona-based World View, $2.8 billion
  • No. 2 Austin-based Apptronik, $966 million
  • No. 3 Mountain View, California-based Lightmatter, $821 million
  • No. 4 Austin-based Function Health, $807 million
  • No. 5. San Francisco-based Niantic, $779 million

“The unique UT Austin advantage is the alignment between the university and the city,” Foundra.ai says. “Unlike schools where the campus ecosystem and the local startup scene are disconnected, Austin’s startup community actively recruits UT students and alumni, and UT programs actively send students into the local ecosystem.”

Texas A&M’s “living laboratory”

UT Austin’s biggest in-state rival, Texas A&M, appeared at No. 79 on the list, down from No. 76 last year. PitchBook tallied 317 A&M-alumni founders at 295 startups. Collectively, those startups have raised $9.8 billion, according to PitchBook.

Among the 317 A&M-affiliated startups, these five have raised the most capital:

  • No. 1 Austin-based RigUp, $817 million
  • No. 2 Austin-based ICON, $543 million
  • No. 3 Scottsdale, Arizona-based HomeLight, $413 million
  • No. 4 Everett, Washington-based Zap Energy, $326 million
  • No. 5 San Diego-based Splice Therapeutics, $320 million

A cornerstone of Texas A&M’s entrepreneurship offerings is the Center for Applied Entrepreneurship and Innovation at the Mays School of Business. The business school says the center “helps students explore, test, build, buy, and transform businesses in real markets.”

“Grounded in Texas as a living laboratory and guided by the Aggie core values, the center advances applied learning through industry engagement, AI-enabled experimentation, and collaboration across Mays and Texas A&M,” the business school says.

The most “exceptional” schools on PitchBook’s list

In announcing its rankings, PitchBook said: “Great entrepreneurs can come from anywhere, but some universities have a truly exceptional track record of attracting and producing future founders.”

The most exceptional universities, based on PitchBook’s criteria, are:

  • No. 1 University of California, Berkeley
  • No. 2 Stanford University
  • No. 3 Harvard University
  • No. 4 Cornell University
  • No. 5 Massachusetts Institute of Technology (MIT)

Planned KBR spinoff scores $1B NOAA deal for extreme weather forecasting

weather watch

Amid a major spinoff, Houston-based KBR's Mission Technology Solutions business has been awarded a five-year contract for up to $1.1 billion from NOAA’s National Weather Service to help predict and combat extreme weather conditions.

Under the follow-on Commercial Data Program National Mesonet Program (CDP NMP) contract, KBR will provide weather and observational data from commercial stations, university and research campuses, and other non-federal providers nationwide. The information collected will assist in predicting severe temperatures and high-impact weather conditions like extreme storms.

"This award underscores KBR's proven track record of delivering vital data that strengthens national forecasting capabilities," Todd May, KBR’s senior vice president of Mission Technology Solutions, said in a news release.

According to a separate release from NOAA, the contract expands upon KBR's existing relationship with the agency. KBR will work with about 70 private industry partners on services such as data recording, collection, aggregation and processing, and will lead the CDP NMP's "network of networks."

“NOAA gathers environmental information from a wide variety of sources, and a growing list of private industry partners have joined our agency to collect this vital data,” Ken Graham, director of NOAA’s National Weather Service, said in the release. “This agreement streamlines the process that turns raw data into the gold-standard forecasts that Americans depend on.”

KBR will utilize its Speed to Mission ImpactSM technology for the project to supply data from across regions, measurement types, and system configurations. Both KBR and NOAA say the expanded data collection contract will help the agency create more accurate and timely forecasts, particularly for severe weather and extreme events, while also creating a path for new weather-observation technologies.

KBR has supported the CDP NMP for more than 9 years. The program will be managed in Greenbelt, Maryland.

"We're driving expanded integration of commercial sensor and data sources into this platform and are honored to know our work helps forecasters give their communities earlier warnings and more time to prepare for dangerous weather,” May added in a release.

KBR’s Mission Technology Solutions business will be rebranded as Trinzic after its planned spin-off, the company announced last month. The spin-off is expected to close in January 2027.

Trinzic will work as an independent, publicly traded company focused on technology and engineering services for the space and national security sector. KBR will remain a separate publicly traded company that will focus on sustainable technology and services to support the energy transition.

This is the salary required to live comfortably in Texas in 2026

Money Matters

A new national report looking at the income it takes to live comfortably in each of the 50 states has revealed Texans need to earn slightly less now than a year ago.

SmartAsset analyzed what a single individual, as well as family of four, must earn to cover minimum basic needs adjusted using the 50/30/20 budgeting rule. The resulting estimate represents the annual, pre-tax income needed to live comfortably in every U.S. state.

A single, full-time worker needs to make $90,563 to live comfortably in the Lone Star State, the report found, which is down a meager 0.2 percent from last year ($90,771).

Under the 50/30/20 budgeting strategy, that means a single Texas earner would have $45,282 to spend on necessities like housing and utilities, $27,169 for discretionary spending, and $18,113 for emergencies or retirement savings.

Texas ranked 34th nationally in SmartAsset's list of states with the highest income needed for a single adult to live "in sustainable comfort" in 2026. Only five other states — Tennessee, Maryland, Louisiana, North Carolina, and Mississippi — saw a decline in the income needed to live comfortably this year.

For a family of four to live comfortably in Texas, income requirements change significantly, according to the findings. To support a two-child household, a family needs $203,424 in combined total household income to be considered financially stable. This is down slightly from 2025, when SmartAsset reported a family of four in needed $204,922 to live comfortably in Texas.

This is a comfortable lifestyle for a family of four in Texas, according to the report:

  • $101,712 dedicated to necessities and living expenses
  • $61,027 dedicated to discretionary spending
  • $40,685 dedicated to emergencies, savings, or debt repaymen

According to the report, a family of four now needs to make at least $200,000 to live comfortably in 40 U.S. states, a figure that is far out of reach for many American families.

"As housing, grocery, transportation and other essential costs pressure household budgets, earning a six-figure salary no longer guarantees financial comfort in much of the U.S.," the report said. "A single adult now needs at least $80,000 a year to live comfortably in every state, while the threshold exceeds $100,000 in nearly half of states. For a family of four, the income needed to live comfortably is as much as $329,000."

Still, earning the minimum income to live comfortably in Texas doesn't guarantee financial stability in the Lone Star State's major cities. Earlier this year, SmartAsset determined single residents in Houston need to make about $90,000 to qualify as financially stable, while families of four need around $205,000.

---

This article originally appeared on CultureMap.com.

View All Listings